Ocular Therapeutix, Inc. (OCUL)
6.50
-0.11
(-1.66%)
USD |
NASDAQ |
Oct 23, 16:00
6.495
0.00 (0.00%)
After-Hours: 20:00
Ocular Therapeutix Enterprise Value : 908.07M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 908.07M |
| October 22, 2026 | 932.23M |
| October 21, 2026 | 903.68M |
| October 20, 2026 | 941.01M |
| October 19, 2026 | 861.96M |
| October 16, 2026 | 989.32M |
| October 15, 2026 | 1.101B |
| October 14, 2026 | 1.062B |
| October 13, 2026 | 1.071B |
| October 12, 2026 | 1.141B |
| October 09, 2026 | 1.136B |
| October 08, 2026 | 1.130B |
| October 07, 2026 | 1.068B |
| October 06, 2026 | 1.093B |
| October 05, 2026 | 1.073B |
| October 02, 2026 | 1.009B |
| October 01, 2026 | 1.082B |
| September 30, 2026 | 1.165B |
| September 29, 2026 | 1.209B |
| September 28, 2026 | 1.162B |
| September 25, 2026 | 1.600B |
| September 24, 2026 | 1.637B |
| September 23, 2026 | 1.677B |
| September 22, 2026 | 1.786B |
| September 21, 2026 | 1.674B |
| Date | Value |
|---|---|
| September 18, 2026 | 1.674B |
| September 17, 2026 | 1.707B |
| September 16, 2026 | 1.648B |
| September 15, 2026 | 1.718B |
| September 14, 2026 | 1.835B |
| September 11, 2026 | 1.784B |
| September 10, 2026 | 1.813B |
| September 09, 2026 | 1.999B |
| September 08, 2026 | 1.977B |
| September 04, 2026 | 1.817B |
| September 03, 2026 | 1.817B |
| September 02, 2026 | 1.874B |
| September 01, 2026 | 1.802B |
| August 31, 2026 | 1.784B |
| August 28, 2026 | 1.756B |
| August 27, 2026 | 1.857B |
| August 26, 2026 | 1.846B |
| August 25, 2026 | 1.870B |
| August 24, 2026 | 1.848B |
| August 21, 2026 | 1.914B |
| August 20, 2026 | 1.916B |
| August 19, 2026 | 2.057B |
| August 18, 2026 | 1.898B |
| August 17, 2026 | 1.819B |
| August 14, 2026 | 1.685B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| EyePoint, Inc. | -123.73M |
| ANI Pharmaceuticals, Inc. | 1.903B |
| Eli Lilly & Co. | 1.245T |
| Corcept Therapeutics, Inc. | 8.967B |
| Veru, Inc. | 15.08M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -78.76M |
| Revenue (Quarterly) | 13.48M |
| Total Expenses (Quarterly) | 92.24M |
| EPS Diluted (Quarterly) | -0.3501 |
| Gross Profit Margin (Quarterly) | 85.08% |
| Profit Margin (Quarterly) | -584.5% |
| Earnings Yield | -21.74% |
| Normalized Earnings Yield | -21.79 |